/Companies

Relay

NASDAQ: RLAYUnicorn · $1.7B

Cambridge, US · Founded 2016 · 9 known investors

Find your way into Relay

Sign up to see every warm intro you have to Relay

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Relay team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.

Founders & leadership

DA
Donald A. BergstromPresident of Research and DevelopmentDonald Bergstrom is Executive Officer at Relay Therapeutics, which develops the Dynamo platform for motion-based drug design. His background includes expertise in oncology drug development, biomarker research, molecular profiling, and clinical trial design across early development phases.
SKSanjiv K. Patel
Sanjiv K. PatelDirector, President and Chief Executive OfficerSanjiv K. Patel is CEO of Relay Therapeutics, a clinical-stage biotech company developing protein dynamics-based drug discovery. He holds prior experience as a surgeon, healthcare management consultant, and in pharmaceutical commercial, marketing, and strategy leadership roles.
SK
Sekar KathiresanNamed on SEC filing
DS
Douglas S. IngramNamed on SEC filing
MM
Mark MurckoNamed on SEC filing
LS
Laura ShawverNamed on SEC filing
BA
Brian AdamsNamed on SEC filing
LH
Linda HillNamed on SEC filing
JR
Jami RubinNamed on SEC filing
TC
Tom CatinazzoExecutive Officer
MP
Mahesh Padval
IP
Imogen Pryce

Investors · 9

Reported raises · per SEC filings

Form D private placements

$30M disclosed across 1 of 2 rounds · 2024–2026

▶$30MraisedJan 2024 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas CatinazzoExecutive Officer
  • Peter RahmerExecutive Officer
  • Sekar KathiresanDirector
  • Douglas S. IngramDirector
  • Sanjiv K. PatelExecutive Officer, Director
  • Mark MurckoDirector
  • Laura ShawverDirector
  • Brian AdamsExecutive Officer
  • Linda HillDirector
  • Jami RubinDirector
  • Donald A. BergstromExecutive Officer
  • Alexis BorisyDirector
Offering amount
$30M
Amount sold
$30M
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$1.7Bvaluation at IPOJul 2020 · $20.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does Relay do?
Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.
Who are Relay's investors?
Relay's investors include Commonweal Ventures, EcoR1 Capital, Foresite Capital, Nat Turner, Nextech Invest, SoftBank Vision Fund, Curie.Bio, General Catalyst and 1 more.
How much funding has Relay raised?
Relay has disclosed $30M raised across 1 of its 2 known rounds.
Where is Relay headquartered?
Relay is headquartered in Cambridge, US.